[1] Batista A, Quattrocchi V, Olivera V, et al. Adjuvant effect of cliptox (TM) on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice[J]. Vaccine, 2010, 28(38): 6361-6366.
[2] Patch J R, Pedersen L E, Toka F N, et al. Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination[J]. Clinical and Vaccine Immunology, 2011, 18(2): 280-288.
[3] Liao Y C, Lin H H, Lin C H, et al. Identification of cytotoxic T lymphocyte epitopes on swine viruses: Multi-epitope design for universal T cell vaccine[J]. PLoS One, 2013, 8(12): e84443.
[4] Cubillos C, De La Torre B G, Jakab A, et al. Enhanced mucosal immunoglobulin a response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide[J]. Journal of Virology, 2008, 82(14): 7223-7230.
[5] Pan Q, Wang H, Ouyang W, et al. Immunogenicity of adenovirus-derived porcine parvovirus-like particles displaying B and T cell epitopes of foot-and-mouth disease[J]. Vaccine, 2016, 34(4): 578-585.
[6] Chai Z, Wang H, Zhou G, et al. Adenovirus-vectored type Asia1 foot-and-mouth disease virus (FMDV) capsid proteins as a vehicle to display a conserved, neutralising epitope of type O FMDV[J]. Journal of Virological Methods, 2013, 188(1-2): 175-182.
[7] Zhang Z, Pan L, Ding Y, et al. Efficacy of synthetic peptide candidate vaccines against serotype-A foot-and-mouth disease virus in cattle[J]. Applied Microbiology and Biotechnology,2015,99(3):1389-1398.
[8] Fang M, Li J, Wang H, et al. Correlation between efficacy and structure of recombinant epitope vaccines against bovine type O foot and mouth disease virus[J]. Biotechnology Letters, 2012, 34(5): 839-847.
[9] Shao J J, Wong C K, Lin T, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine [J]. Clinical and Vaccine Immunology, 2011, 18(1): 143-149.
[10] Jung J G, Lee Y J, Velmurugan N, et al. High-yield production of the VP1 structural protein epitope from serotype O foot-and-mouth disease virus in Escherichia coli[J]. Journal of Industrial Microbiology & Biotechnology, 2013, 40(7): 705-713.
[11] Diazsan S F, Medina G N, Ramirez-Medina E, et al. Synonymous deoptimization of foot-and-mouth disease virus causes attenuation in vivo while inducing a strong neutralizing antibody response[J]. Journal of Virology, 2016, 90(3): 1298-1310.
[12] Wei H, Fang M, Wan M, et al. Influence of hydrophilic amino acids and GC-content on expression of recombinant proteins used in vaccines against foot-and-mouth disease virus in Escherichia coli[J]. Biotechnology Letters, 2014, 36(4): 723-729.
[13] Seago J, Jackson T, Doel C, et al. Characterization of epitope-tagged foot-and-mouth disease virus [J]. Journal of General Virology,2012,93(11):2371-2381.
[14] Yang B, Yang F, Zhang Y, et al. The rescue and evaluation of FLAG and HIS epitope-tagged Asia 1 type foot-and-mouth disease viruses[J]. Virus Research, 2016, 213(2): 246-254.
[15] Zheng H, He J, Guo J, et al. Genetic characterization of a new pandemic Southeast Asia topotype strain of serotype O foot-and-mouth disease virus isolated in China during 2010 [J]. Virus Genes, 2012, 44(1): 80-88.
[16] Mahapatra M, Hamblin P, Paton D J. Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals [J]. Journal of General Virology, 2012, 93(3): 488-493.
[17] McLaughlin K, Seago J, Robinson L, et al. Hsp70 enhances presentation of FMDV antigen to bovine CD4(+) T cells in vitro[J]. Veterinary Research, 2010, 41(3):36.
[18] Pei X, Wang Q, Meng L, et al. Chaperones-assisted soluble expression and maturation of recombinant co-type nitrile hydratase in Escherichia coli to avoid the need for a low induction temperature [J]. Journal of Biotechnology, 2015, 203(6): 9-16.
[19] Houen G. Peptide Antibodies: Methods and Protocols, Methods in Molecular Biology[M].New York:Springer,2015.
[20] Ren J, Yang L, Xu H, et al. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle[J]. Vaccine, 2011, 29(45): 7960-7965.
[21] Cao Y, Lu Z, Li D, et al. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease virus in pigs vaccinated with multi-epitope protein vaccine incorporated with poly(I:C)[J]. Veterinary Microbiology, 2014, 168(2-4): 294-301.
[22] Gülçe Ïz S, Doskaya M, Borrego B, et al. Co-expression of the Bcl-xL antiapoptotic protein enhances the induction of Th1-like immune responses in mice immunized with DNA vaccines encoding FMDV B and T cell epitopes[J]. Veterinary Research Communications, 2013, 37(3): 187-196.
[23] Blanco E, Cubillos C, Moreno N, et al. B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot-and-mouth disease peptide vaccines [J]. Clinical & Developmental Immunology, 2013(2013):e475960.
[24] Blanco E, Guerra B, De La Torre B G, et al. Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide [J]. Antiviral Research, 2016, 129(5): 74-80.